Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Mar 25, 2024 11:07pm
53 Views
Post# 35952160

RE:RE:The Take-Over

RE:RE:The Take-OverI am trying to follow your math.  I may be wrong but in your formula you are assuming that Andrew's new "phantom" company is offering to purchase Replicel and all it's assets which will account for 92 % of the company leaving the rest of us with 8% Royalty on any future profits.

I think that may not be how he has layed out his confusing offer.   If we as shareholders are rolled into this new company would we not be have the same share of the 65,000,000 outstanding shares as we presently have which makes Andrew owning 17,000,000 of the 65,000,000 ?

If that is not the case this offer is the biggest load of shite and he can't be serious that we are going buy into this.
Also was there not a "poisen pill" set up a number of years ago ?

I am assuming that Andrew and his cronies are seeing the push back here and if the truly want this company they may rethink this and come back with an actual buy-out offer.
<< Previous
Bullboard Posts
Next >>